Effects of cysteamine administration on the in vivo incorporation of [35S]cysteine into somatostatin-14, somatostatin-28, arginine vasopressin, and oxytocin in rat hypothalamus

Endocrinology. 1986 Sep;119(3):1292-7. doi: 10.1210/endo-119-3-1292.

Abstract

The effect of cysteamine injection on the in vivo incorporation of [35S]cysteine into somatostatin-14 (SRIF-14), SRIF-28, arginine vasopressin (AVP), and oxytocin (OXT) in rat hypothalamus was studied. [35S]Cysteine was injected into the third ventricle 1 h, 4 h, or 1 week after cysteamine (300 mg/kg, sc) injection; animals were killed 4 h later. The drug was found to substantially reduce immunoreactive SRIF levels, but not OXT or AVP, 4 h after its injection. Cysteamine also caused large reductions in label incorporation into SRIF-14, SRIF-28, and OXT 1 and 4 h after drug injection. However, [35S]cysteine incorporation into AVP was increased substantially at these time points, while that into acid-precipitable protein was normal. One week after cysteamine injection, label incorporation into all hypothalamic peptides was normal. Cysteine specific activity was also measured after [35S]cysteine injection and was found to be similar in treatment and control groups. The results suggest that cysteamine inhibits the syntheses of SRIF-14, SRIF-28, and OXT and stimulates that of AVP.

Publication types

  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Arginine Vasopressin / metabolism*
  • Cysteamine / pharmacology*
  • Cysteine / metabolism*
  • Hypothalamus / drug effects*
  • Hypothalamus / metabolism
  • Male
  • Oxytocin / metabolism*
  • Rats
  • Rats, Inbred Strains
  • Somatostatin / metabolism*
  • Somatostatin-28
  • Time Factors

Substances

  • Arginine Vasopressin
  • Oxytocin
  • Somatostatin
  • Cysteamine
  • Somatostatin-28
  • Cysteine